First-Time Wyoming Hunter Had To Watch Elk Suffer After Another Took Bad Shot
Reply
Nature (2023)Cite this article
https://www.nature.com/articles/s41586-023-06625-0
Illegal harvesting and trading of wildlife have become major threats to global biodiversity and public health1,2,3. Although China is widely recognized as an important destination for wildlife illegally obtained abroad4, little attention has been given to illegal hunting within its borders. Here we extracted 9,256 convictions for illegal hunting from a nationwide database of trial verdicts in China spanning January 2014 to March 2020. These convictions involved illegal hunting of 21% (n = 673) of China’s amphibian, reptile, bird and mammal species, including 25% of imperilled species in these groups. Sample-based extrapolation indicates that many more species were taken illegally during this period. Larger body mass and range size (for all groups), and proximity to urban markets (for amphibians and birds) increase the probability of a species appearing in the convictions database. Convictions pertained overwhelmingly to illegal hunting for commercial purposes and involved all major habitats across China. A small number of convictions represented most of the animals taken, indicating the existence of large commercial poaching operations. Prefectures closer to urban markets show higher densities of convictions and more individual animals taken. Our results suggest that illegal hunting is a major, overlooked threat to biodiversity throughout China.
By Andrew Silver and Selena Li
October 23, 20236:28 AM PDTUpdated a day ago

Show more companies
SHANGHAI/HONG KONG, Oct 23 (Reuters) – Three listed Chinese drugmakers, whose investors include or use some of the world’s biggest banks, used parts of endangered animals as ingredients in their products, an environmental group said in a report published Monday.
The London-based Environmental Investigation Agency (EIA) urged investors in Beijing Tong Ren Tang group (600085.SS), Tianjin Pharmaceutical group (600329.SS) and Jilin Aodong Pharmaceutical Group (000623.SZ) to divest their stakes.
Advertisement · Scroll to continue
Beijing Tong Ren Tang and Tianjin Pharmaceutical group did not respond to Reuters’ emails or calls seeking comment. Jilin Aodong Pharmaceutical Group could not be reached for comment.
The three are among 72 firms which non-profit organisation EIA said used body parts of threatened leopards and pangolins as ingredients in at least 88 traditional Chinese medicine (TCM) products.
The group said it focused on the pharmaceutical companies because they are publicly listed and display products that include leopard or pangolin parts on their websites.
Advertisement · Scroll to continueReport this ad
TCM manufacturers often publicly tout the efficacy of such ingredients and list them on their product packages.
“It’s particularly disappointing to see so many major banks and financial institutions effectively endorsing this damaging exploitation,” Avinash Basker, a legal and policy specialist for EIA, said in a media release.
“They need to divest from TCM manufacturers using threatened species at the soonest opportunity.”